PMID- 11776757
OWN - NLM
STAT- MEDLINE
DCOM- 20020617
LR  - 20221207
IS  - 1084-9785 (Print)
IS  - 1084-9785 (Linking)
VI  - 16
IP  - 5
DP  - 2001 Oct
TI  - HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
PG  - 401-9
AB  - BACKGROUND: The natural history of malignancies, the response to cytokine-based 
      therapy and survival of patients may be partly determined by the human leukocyte 
      antigen (HLA) phenotype. Here, we investigated in a retrospective analysis the 
      correlation of the HLA phenotype of 73 prognostic favored patients with advanced 
      renal cell carcinoma to (a) the expected HLA distribution in Caucasians, (b) the 
      susceptibility or resistance to metastatic sites, (c) response to cytokine-based 
      therapy and (d) sustained cytokine-induced effective tumor control. METHODS: We 
      retrospectively determined the MHC class I and II antigens in patients with 
      metastatic renal cell carcinoma selected by survival. Antigens were serologically 
      typed by standard lymphocytotoxicity techniques. For statistical analysis, we 
      calculated the probability of the presented HLA antigens in correlation to the 
      expected Caucasian HLA phenotypes. An independent confirmation was performed by 
      using the chi-square and two-tailed Fisher's exact test. RESULTS: Various HLA 
      antigens deviated significantly from the normal distribution in the Caucasian 
      population. HLA.B44 was the only antigen associated (p < 0.01) with the absence 
      of lung and presence of bone metastases, while it did not impact on overall 
      survival or response to therapy. A1 (p < 0.0001, p < 0.002) and B8 (p < 0.009, p 
      < 0.04) alleles were more frequently expressed in responding patients than 
      expected from the normal distribution in Caucasians and that observed in 
      non-responding patients, respectively. The HLA analysis of patients achieving a 
      durable complete remission showed a significantly higher frequency of expression 
      of the A1 and B8 antigens and furthermore of the B14 antigen (p < 0.05). 
      CONCLUSIONS: Our data underline the pivotal role of the MHC complex in 
      controlling and regulating the cellular immune response in renal cell cancer. We 
      could identify HLA antigens, which correlate with response to cytokine-treatment, 
      with a long-lasting effective tumor control and prolonged overall survival.
FAU - Franzke, A
AU  - Franzke A
AD  - Department of Hematology and Oncology, Medizinische Hochschule Hannover, Germany. 
      franzke.anke@mh-hannover.de
FAU - Buer, J
AU  - Buer J
FAU - Probst-Kepper, M
AU  - Probst-Kepper M
FAU - Lindig, C
AU  - Lindig C
FAU - Framzle, M
AU  - Framzle M
FAU - Schrader, A J
AU  - Schrader AJ
FAU - Ganser, A
AU  - Ganser A
FAU - Atzpodien, J
AU  - Atzpodien J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Proteins)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm/*analysis
MH  - Antimetabolites, Antineoplastic/administration & dosage/therapeutic use
MH  - Bone Neoplasms/secondary
MH  - Carcinoma, Renal Cell/*drug therapy/immunology/mortality/secondary
MH  - Female
MH  - Fluorouracil/administration & dosage/therapeutic use
MH  - Gene Frequency
MH  - HLA Antigens/*analysis/genetics
MH  - Humans
MH  - Immunologic Factors/administration & dosage/*therapeutic use
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage/*therapeutic use
MH  - Interleukin-2/administration & dosage/*therapeutic use
MH  - Kidney Neoplasms/*drug therapy/immunology/mortality
MH  - Life Tables
MH  - Lung Neoplasms/secondary
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Prognosis
MH  - Recombinant Proteins
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - White People
EDAT- 2002/01/05 10:00
MHDA- 2002/06/18 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/06/18 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
AID - 10.1089/108497801753354302 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2001 Oct;16(5):401-9. doi: 10.1089/108497801753354302.